Document is current
Any future updates will be listed below
-
Authors
Diaz, Luis Antonio https://orcid.org/0000-0002-8540-4930
Thiele, Maja https://orcid.org/0000-0003-1854-1924
Louvet, Alexandre https://orcid.org/0000-0002-5293-007X
Lee, Brian P. https://orcid.org/0000-0003-2108-1287
Ajmera, Veeral https://orcid.org/0000-0001-5626-0942
Tavaglione, Federica https://orcid.org/0000-0002-1720-4355
Hsu, Cynthia L. https://orcid.org/0000-0002-2604-1340
Huang, Daniel Q. https://orcid.org/0000-0002-5165-5061
Pose, Elisa
Bataller, Ramon https://orcid.org/0000-0002-1119-7799
McClain, Craig
Mellinger, Jessica
Tincopa, Monica
Mitchell, Mack C. https://orcid.org/0000-0001-9018-7988
Ratziu, Vlad
Rinella, Mary E. https://orcid.org/0000-0003-0620-9705
Sarin, Shiv K. https://orcid.org/0000-0002-0544-5610
Shah, Vijay H. https://orcid.org/0000-0001-7620-573X
Szabo, Gyongyi
Wong, Vincent Wai-Sun
Bansal, Meena B. https://orcid.org/0000-0002-7501-2191
Leggio, Lorenzo https://orcid.org/0000-0001-7284-8754
Kamath, Patrick S. https://orcid.org/0000-0002-7888-1165
Krag, Aleksander https://orcid.org/0000-0002-9598-4932
Sanyal, Arun J. https://orcid.org/0000-0001-8682-5748
Arrese, Marco
Arab, Juan Pablo https://orcid.org/0000-0002-8561-396X
Anstee, Quentin M. https://orcid.org/0000-0002-9518-0088
Mathurin, Philippe
Loomba, Rohit https://orcid.org/0000-0002-4845-9991
- License Information
-
More Information
Article History
Accepted: 28 August 2025
First Online: 26 September 2025
Competing interests
: M. Thiele received speaker’s fee from Echosens, Madrigal Pharmaceuticals, Takeda and Novo Nordisk; received advisory fees from Boehringer Ingelheim, AstraZeneca, Novo Nordisk and GSK; and is co-founder of Evido. D.Q.H. has served as an advisory board member for Gilead Sciences and Roche. B.P.L. served as a consultant or advisory board member for AltImmune, DURECT, Gilead Sciences, GSK, HepaTx, Ipsen and Novo Nordisk; and received a research grant from Siemens Healthineers. R.B. consults for Boehringer Ingelheim, GSK and Novo Nordisk. J.M. serves as advisory board member for 89bio, Eli Lilly, GSK and Novo Nordisk. M.C.M. serves as an advisory board member for GSK. M.E.R. is scientific adviser or consultant for Akero Therapeutics, Boehringer Ingelheim, Cytodyn, Echosens, GSK, Intercept Pharmaceuticals, Madrigal Pharmaceuticals, NGM Biopharmaceuticals, Novo Nordisk and Sonic Incytes. V.W.-S.W. served as a consultant or advisory board member for AbbVie, AstraZeneca, Boehringer Ingelheim, Echosens, Eli Lilly, Gilead Sciences, Intercept Pharmaceuticals, Inventiva, Merck, Novo Nordisk, Pfizer, Sagimet Biosciences, TARGET PharmaSolutions and Visirna; served as a speaker for Abbott, AbbVie, Echosens, Gilead Sciences, Novo Nordisk and Unilab; has received a research grant from Gilead Sciences; and is a co-founder of Illuminatio Medical Technology. A.K. has served as a speaker for Norgine, Novo Nordisk and Siemens; participated in advisory boards for Boehringer Ingelheim, GSK, Novo Nordisk and Siemens, all outside the submitted work; has received research support from AstraZeneca, Echosense, Nordic Bioscience and Siemens; and is a board member and co-founder of Evido. M.A. consults for AstraZeneca and Inventiva; and has served as a speaker for Siemens. R.L. serves as a consultant to 89bio, Aardvark Therapeutics, Altimmune, Amgen, Anylam/Regeneron, Arrowhead Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, CohBar, Eli Lilly, Galmed, Gilead Sciences, Glympse Bio, Hightide, Inipharma, Intercept Pharmaceuticals, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, Metacrine, NGM Biopharmaceuticals, Novartis, Novo Nordisk, Pfizer, Sagimet Bioscience, Terns Pharmaceuticals, Theratechnologies and Viking Therapeutics; his institutions received research grants from Arrowhead Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galectin Therapeutics, Galmed Pharmaceuticals, Gilead Sciences, Hanmi, Intercept Pharmaceuticals, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, Novo Nordisk, Pfizer, Sonic Incytes and Terns Pharmaceuticals; and he is a co-founder of LipoNexus. All other authors declare no competing interests.
